Published: 12 August 2021
Author(s): Corrado Campochiaro, Nicola Farina, Alessandro Tomelleri, Roberto Ferrara, Chiara Lazzari, Giacomo De Luca, Alessandra Bulotta, Diego Signorelli, Anna Palmisano, Davide Vignale, Giovanni Peretto, Simone Sala, Antonio Esposito, Marina Garassino, Vanesa Gregorc, Lorenzo Dagna
Section: Original article

Immune checkpoint inhibitors (ICI) have been a major breakthrough in the treatment scenario of patients affected by solid cancers and haematological malignancies. First-line pembrolizumab, a programmed cell death -1 (PD-1) inhibitor, was recently shown to lead to a two-fold increase of overall survival rate in a subgroup of naïve non-small-cell lung cancer (NSCLC) patients when compared to chemotherapy [1]. However, ICI came together with the occurrence of unique clinical manifestations called immune-related adverse events (irAEs) [2,3].

Newsletters

Stay informed on our latest news!